Background For locally advanced rectal cancer (LARC) patients who receive neoadjuvant
chemoradiotherapy (nCRT), there are no reliable indicators to accurately predict …

Purpose: No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is
currently available. We assessed in LARC whether a diagnostic biopsy-adapted …

PURPOSE No biomarker capable of improving selection and monitoring of patients with
rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic …

Opinion statement Since total neoadjuvant treatment achieves almost 30% pathologic
complete response, organ preservation has been increasingly debated for good responders …

Simple Summary Rectal cancer patients are often treated with radiotherapy, either alone or
combined with chemotherapy, prior to surgery to enable radical surgery on a non-resectable …

Purpose To investigate the clinical factors affecting pathological complete response (pCR)
after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) …

Surgical research has been under‐powered, under‐funded and under‐delivered for
decades. A solution may be to form large research collaborations and thereby enable …

Simple Summary Regional hyperthermia added to standard preoperative
chemoradiotherapy for locally advanced and recurrent rectal cancer gives a high complete …

Background Liquid biopsy is a minimally invasive procedure investigating tumor mutations.
Methods In our retrospective study, we investigated whether molecular therapy monitoring of …

Purpose In the search for candidate predictive biomarkers to evaluate response to
neoadjuvant chemoradiotherapy (nCRT) in rectal cancer, only a few studies report …